Clinical Trials Directory

Trials / Completed

CompletedNCT04720027

Long Term Study of 3 Radiofrequency Devices

Long Term Outcomes of the Double Blind Randomised Controlled Trial of Radiofrequency Thermal Ablation Treatments of Great Saphenous Varicose Veins: Closurefast vs. RFITT vs. EVRF

Status
Completed
Phase
Study type
Observational
Enrollment
117 (actual)
Sponsor
Worcestershire Acute Hospitals NHS Trust · Academic / Other
Sex
All
Age
23 Years
Healthy volunteers
Accepted

Summary

To establish which of the radiofrequency venous ablation modalities studied in the original 3RF study (Venefit (Closurefast), vs. Radiofrequency induced Thermal Therapy vs. Endovenous Radiofrequency) is most effective in relieving patients' symptoms and signs from varicose veins disease, and in maintaining absence of reflux in the treated vein segment (of the great saphenous vein (GSV)) 5 years following surgery.

Detailed description

Results of randomised trials and meta-analyses have shown that endovenous thermal ablation of the GSV using radiofrequency ablation or laser is associated with improved recovery compared with conventional surgery. Furthermore, radiofrequency ablation (using the Closurefast device) has been shown to cause less pain and require less analgesic intake than laser treatment. At the time the 3 RF study was conceived there were two other radiofrequency devices that were marketed to have theoretical advantages over the Closurefast technique. All three devices were in use in clinical practice (including at Worcestershire Royal Hospital) in 2013. The initial study focused on clinical results (up to 12 months) and anatomical results (up to 6 months) and remains the only clinical trial to date that has directly compared the outcomes of radiofrequency thermal ablation devices. This second (long term) phase of the study aims to assess which of the radiofrequency venous ablation modalities studied in the original 3RF study (Venefit (Closurefast), vs. Radiofrequency induced Thermal Therapy vs. Endovenous Radiofrequency) is most effective in relieving patients' symptoms and signs from varicose veins disease, and in maintaining absence of reflux in the treated vein segment (of the great saphenous vein (GSV)) 5 years following surgery.

Conditions

Interventions

TypeNameDescription
DIAGNOSTIC_TESTDuplex imagingCompletion of AVVQ and EQ5D questionnairs

Timeline

Start date
2021-06-10
Primary completion
2022-03-31
Completion
2022-06-25
First posted
2021-01-22
Last updated
2022-08-15

Locations

1 site across 1 country: United Kingdom

Source: ClinicalTrials.gov record NCT04720027. Inclusion in this directory is not an endorsement.